Viral hemorrhagic fevers including hantavirus pulmonary syndrome in the Americas

Clinics in Laboratory Medicine

Volumn 22, Issue 4, 2002, Pages 981-1020

  Bausch, Daniel G ^a   Ksiazek, Thomas G ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARENAVIRUS; CLINICAL FEATURE; DENGUE; DENGUE VIRUS; HANTAVIRUS; HANTAVIRUS PULMONARY SYNDROME; HEMORRHAGIC FEVER; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; VIRUS MORPHOLOGY; YELLOW FEVER FLAVIVIRUS; CROSS INFECTION; DIFFERENTIAL DIAGNOSIS; HUMAN; VIROLOGY; VIRUS HEMORRHAGIC FEVER; YELLOW FEVER;

CROSS INFECTION; DENGUE HEMORRHAGIC FEVER; DIAGNOSIS, DIFFERENTIAL; HEMORRHAGIC FEVER WITH RENAL SYNDROME; HEMORRHAGIC FEVERS, VIRAL; HUMANS; YELLOW FEVER;

EID: 0036892084     PISSN: 02722712     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0272-2712(02)00019-7     Document Type: Review

References (147)

1. Padula PJ, Edelstein A, Miguel SDL, Lopez NM, Rossi CM, Rabinovich RD. Hantavirus Pulmonary Syndrome outbreak in Argentina: Molecular evidence for person-to-person transmission of Andes virus. Virology 1998;241:323-30.
2. Wells RM, Estani SS, Yadon ZE, et al. An unusual hantavirus outbreak in southern Argentina: Person-to-person transmission? Emerg Infect Dis 1997;3:171-4.
3. Centers for Disease Control and Prevention. Fatal illnesses associated with a new World Arenavirus, California, 1999-2000. MMWR 2000;49:709-11.
4. Fontenille D, Diallo M, Mondo M, Ndiaye M, Thonnon J. First evidence of natural vertical transmission of yellow fever virus in Aedes aegypti, its epidemic vector. Trans R Soc Trop Med Hyg 1997;91:533-5.
5. Robertson SE, Hull BP, Tomori O. Yellow fever. A decade of resurgence. JAMA 1996;276:1157-62.
6. World Health Organization. Yellow fever, 1996-1997, Part I. Wkly Epidemiol Rec 1998;46:354-9.
7. Gubler DJ. Dengue and dengue hemorrhagic fever. Clin Microbiol Rev 1998;11:480-6.
8. Ibanez-Bernal S, Briseno B, Mutebi JP, et al. First record in America of Aedes albopictus naturally infected with dengue virus during the 1995 outbreak at Reynosa, Mexico. Med Vet Entomol 1997;11:305-9.
9. World Health Organization report on global surveillance of epidemic-prone infectious diseases. Dengue and dengue haemorrhagic fever. Communicable Disease Surveillance and Response (CSR) 2000. p. 1-7.
10. Pinheiro FP, Corber SJ. Global situation of dengue and dengue haemorrhagic fever, an its emergence in the Americas. World Health Stat Q 1997;50:161-9.
11. Centers for Disease Control and Prevention. Dengue fever at the U.S. Mexico border, 1995-96. MMWR 1996;45:841-4.
12. Centers for Disease Control and Prevention. Underdiagnosis of dengue-Laredo Texas, 1999. MMWR 2001;50:57-9.
13. Johnson KM, Kuns ML, Mackenzie RB, Webb PA, Yunker CE. Isolation of Machupo virus from wild rodent Calomys callosus. Am J Trop Med Hyg 1966;15:103-6.
14. Tesh RB, Wilson ML, Salas R, et al. Field studies on the epidemiology of Venezuelan hemorrhagic fever - Implication of the cotton rat Sigmodon alstoni as the probable rodent reservoir. Am J Trop Med Hyg 1993;49:227-35.
15. Bowen MD, Peters CJ, Nichol ST. Phylogenetic analysis of the Arenaviridae: Patterns of virus evolution and evidence for cospeciation between arenaviruses and their rodent hosts. Mol Phylogenet Evol 1997;8:301-16.
16. Mills JN, Ellis BA, Childs JE, et al. Prevalence of infection with Junin virus in rodent populations in the epidemic area of Argentine hemorrhagic fever. Am J Trop Med Hyg 1994;51:554-62.
17. Mills JN, Ellis BA, McKee Jr KT, et al. A longitudinal study of Junin virus activity in the rodent reservoir of Argentine hemorrhagic fever. Am J Trop Med Hyg 1992;47:749-63.
18. Vitullo AD, Hodara VL, Merani MS. Effect of persistent infection with Junin virus on growth and reproduction of its natural reservoir. Calomysmusculinus. Am J Trop Med Hyg 1987;37:663-9.
19. Webb PA, Justines GJ, Johnson KM. Infection of wild and laboratory animals with Machupo and Latino viruses. Bull World Health Organ 1975;52:493-9.
20. Fulhorst CF, Ksiazek TG, Peters CJ, Tesh RB. Experimental infection of the cane mouse Zygodontomys brevicauda (family Muridae) with Guanarito virus (Arenaviridae), the etiologic agent of Venezuelan hemorrhagic fever. J Infect Dis 1999;180:966-9.
21. Kenyon RH, McKee KT Jr., Zack PM, et al. Aerosol infection of rhesus macaques with Junin virus. Intervirology 1992;33:23-31.
22. Maiztegui JI, Feuillade MR, Briggiler AM. Progressive extension of the endemic area and changing incidence of Argentine hemorrhagic fever. Med Microbiol Immunol (Berl) 1986;175:149-52.
23. Mills JN, Calderon G, Ellis BA, et al. New findings on Junin virus infection in rodents inside and outside the endemic area of hemorrhagic fever in Argentina. Medicina (B Aires) 1991;51:519-23.
24. Mills JN, Ellis BA, Ksiazek TG, et al. Junin virus activity in rodents from endemic and nonendemic loci in central Argentina. Am J Trop Med Hyg 1991;44:589-97.
25. Centers for Disease Control and Prevention. Bolivian hemorrhagic fever - El Beni Department, Bolivia, 1994. MMWR 1994;43:942-5.
26. De Manzione N, Salas RA, Paredes H, et al. Venezuelan hemorrhagic fever: Clinical and epidemiological studies of 165 cases. Clin Infect Dis 1998;26:308-13.
27. Fulhorst CF, Bowen MD, Salas RA, et al. Natural rodent host associations of Guanarito and Pirital viruses (family arenaviridae) in central Venezuela. Am J Trop Med Hyg 1999;61:325-30.
28. Mackenzie RB. Epidemiology of Machupo virus infection. I. Pattern of human infection, San Joaquin, Bolivia, 1962-1964. Am J Trop Med Hyg 1964;14:808-13.
29. Peters CJ, Kuehne RW, Mercado RR, Le Bow RH, Spertzel RO, Webb PA. Hemorrhagic fever in Cochabamba, Bolivia, 1971. Am J Epidemiol 1974;99:425-33.
30. Armstrong LR, Dembry LM, Rainey PM, et al. Management of a Sabia virus-infected patient in a US hospital. Infect Control Hosp Epidemiol 1999;20:176-82.
31. Lisieux T, Coimbra M, Nassar ES, et al. New Arenavirus isolated in Brazil. Lancet 1994;343:391-2.
32. Ryder RW, Gandsman EJ. Laboratory-acquired Sabia virus infection. N Engl J Med 1995;333:1716.
33. Johnson KM, Halstead SB, Cohen SN. Hemorrhagic fevers of Southeast Asia and South America: A comparative appraisal. Prog Med Virol 1967;9:105-58.
34. Kuns ML. Epidemiology of Machupo virus infection. II. Ecological and control studies of hemorrhagic fever. Am J Trop Med Hyg 1965;14:813-16.
35. Glass GE, Childs JE, Korch GW, LeDuc JW. Association of intraspecific wounding with hantaviral infection in wild rats (Rattus norvegicus). Epidemiol Infect 1988;101:459-72.
36. Mills JN, Ksiazek TG, Ellis BA, et al. Patterns of association with host and habitat: Antibody reactive with Sin Nombre virus in small mammals in the major biotic communities of the southwestern United States. Am J Trop Med Hyg 1997;56:273-84.
37. Xu ZY, Guo CS, Wu YL, Zhang XW, Liu K. Epidemiological studies of hemorrhagic fever with renal syndrome: Analysis of risk factors and mode of transmission. J Infect Dis 1985;152:137-44.
38. Yanagihara R. Hantavirus infection in the United States: Epizootiology and epidemiology. Rev Infect Dis 1990;12:449-57.
39. Lee HW, French GR, Lee PW, Baek LJ, Tsuchiya K, Foulke RS. Observations on natural and laboratory infection of rodents with the etiologic agent of Korean hemorrhagic fever. Am J Trop Med Hyg 1981;30:477-82.
40. Dournon E, Moriniere B, Matheron S, et al. HFRS after a wild rodent bite in the haute-Savoie and a risk of exposure to Hantaan-like virus in a Paris laboratory. Lancet 1984;1:676-7.
41. Kawamata J, Yamanouchi T, Dohmae K, et al. Control of laboratory acquired hemorrhagic fever with renal syndrome (HFRS) in Japan. Lab Anim Sci 1987;37:431-6.
42. Peters CJ, Simpson GL, Levy H. Spectrum of hantavirus infection: Hemorrhagic fever with renal syndrome and hantavirus pulmonary syndrome. Annu Rev Med 1999;50:531-45.
43. Enria DA, Pinheiro F. Rodent-borne emerging viral zoonosis. Hemorrhagic fevers and hantavirus infections in South America. Infect Dis Clin North Am 2000;14:167-84.
44. Schmaljohn C, Hjelle B. Hantaviruses: A global disease problem. Emerg Infect Dis 1997;3:95-104.
45. Childs JE, Ksiazek TG, Spiropoulou CF, et al. Serologic and genetic identification of Peromyscus maniculatus as the primary rodent reservoir for a new hantavirus in the southwestern United States. J Infect Dis 1994;169:1271-80.
46. Mills JN, Ksiazek TG, Peters CJ, Childs JE. Long-term studies of hantavirus reservoir populations in the southwestern United States: A synthesis. Emerg Infect Dis 1999;5:135-42.
47. Armstrong LR, Zaki SR, Goldoft MJ, et al. Hantavirus pulmonary syndrome associated with entering or cleaning rarely used, rodent-infested structures. J Infect Dis 1995;172:1166.
48. Calderon G, Pini N, Bolpe J, et al. Hantavirus reservoir hosts associated with peridomestic habitats in Argentina. Emerg Infect Dis 1999;5:792-97.
49. Childs JE, Krebs JW, Ksiazek TG, et al. A household-based, case-control study of environmental factors associated with hantavirus pulmonary syndrome in the southwestern United States. Am J Trop Med Hyg 1995;52:393-97.
50. Zeitz PS, Graber JM, Voorhees RA, et al. Assessment of occupational risk for hantavirus infection in Arizona and New Mexico. J Occup Environ Med 1997;39:463-67.
51. Engelthaler DM, Levy CE, Fink TM, Tanda D, Davis T. Short report: Decrease in seroprevalence of antibodies to hantavirus in rodents from 1993-1994 hantavirus pulmonary syndrome case sites. Am J Trop Med Hyg 1998;58:737-8.
52. Lee HW, Lee PW, Baek LJ, Song CK, Seong IW. Intraspecific transmission of Hantaan virus, etiologic agent of Korean hemorrhagic fever, in the rodent Apodemus agrarius. Am J Trop Med Hyg 1981;30:1106-12.
53. Engelthaler DM, Mosley DG, Cheek JE, et al. Climatic and environmental patterns associated with hantavirus pulmonary syndrome, four corners region, United States. Emerg Infect Dis 1999;5:87-94.
54. Hjelle B, Glass GE. Outbreak of hantavirus infection in the Four Corners region of the United States in the wake of the 1997-1998 El Nino-Southern Oscillation. J Infect Dis 2000;181:1569-73.
55. Boone JD, McGwire KC, Otteson EW, et al. Remote sensing and geographic information systems: Charting sin nombre virus infections in deer mice. Emerg Infect Dis 2000;6:248-58.
56. Cantoni G, Padula P, Calderon G, et al. Seasonal variation in prevalence of antibody to hantaviruses in rodents from southern Argentina. Trop Med Int Health 2001;6:811-6.
57. Mills JN, Johnson JS, Ksiazek TG, et al. A survey of hantavirus antibody in small-mammal populations in selected United States National Parks. Am J Trop Med Hyg 1998;58:525-32.
58. Root JJ, Calisher CH, Beaty BJ. Relationships of deer mouse movement, vegetative structure, and prevalence of infection with Sin Nombre virus. J Wildl Dis 1999;35:311-8.
59. LeDuc JW, Smith GA, Pinheiro FP, Vasconcelos PFC, Rosa EST, Maiztegui JI. Isolation of Hantaan-related virus from Brazilian rats and serologic evidence of its widespread distribution in South America. Am J Trop Med Hyg 1985;34:810-5.
60. Tsai TF, Bauer SP, Sasso DR, et al. Serological and virological evidence of a Hantaan virus-related enzootic in the United States. J Infect Dis 1985;152:126-6.
61. Milei J, Bolomo NJ. Myocardial damage in viral hemorrhagic fevers. Am Heart J 1992;104:1385-91.
62. De Bracco MME, Rimoldi MT, Cossio PM, et al. Argentine hemorrhagic fever. Alterations of the complement system and anti-Junin-virus humoral response. N Engl J Med 1978;299:216-21.
63. Monath TP. Yellow fever. In: Guerrant RL, Walker DH, Weller PF, editors. Tropical Infectious Diseases: Principles, Pathogens, and Practice. Philadelphia: Churchill Livingstone; 1999. p. 1253-64.
64. Vallejos DA, Ambrosio AM, Feuillade MR, Maiztegui JI. Lymphocyte subsets alteration in patients with argentine hemorrhagic fever. J Med Virol 1989;27:160-3.
65. Bharadwaj M, Nofchissey R, Goade D, Koster F, Hjelle B. Humoral immune responses in the hantavirus cardiopulmonary syndrome. J Infect Dis 2000;182:43-8.
66. Morens DM. Antibody-dependent enhancement of infection and the pathogenesis of viral disease. Clin Infect Dis 1994;19:500-12.
67. Sullivan NJ. Antibody-mediated enhancement of viral disease. Curr Top Microbiol Immunol 2001;260:145-69.
68. Smyth AG, Powell GM. The electrocardiogram in hemorrhagic fever. Am Heart J 1954;47:218-40.
69. Monath TP. Yellow fever: A medically neglected disease. Rev Infect Dis 1987;9:165-75.
70. Oudart JL, Rey M. Proteinuria, proteinaemia, and serum transaminase activity in 23 confirmed cases of yellow fever. Bull World Health Organ 1970;42:95-102.
71. Maiztegui JI. Clinical and epidemiological patterns of Argentine haemorrhagic fever. Bull World Health Organ 1975;52:567-75.
72. Vainrub B, Salas R. Latin American hemorrhagic fever. Infect Dis Clin North Am 1994;8:47-59.
73. Biquard C, Figini HA, Monteverde DA, Somoza MJ, Alvarez F. Estudio neurológico de 120 casos de fiebre hemorrágica Argentina. Prensa Med Argent 1969;56:605-14.
74. Heller MV, Marta RF, Sturk A, et al. Early markers of blood coagulation and fibrinolysis activation in Argentine hemorrhagic fever. Thromb Haemost 1995;73:368-73.
75. Molinas FC, De Bracco MME, Maiztegui JI. Coagulation studies in Argentine hemorrhagic fever. J Infect Dis 1981;143:1-6.
76. Briggiler AM, Levis S, Enria DA, Ambrosio AM, Maitegui JI. Fiebre hemorragica Argentina (FHA) en la mujer embarazada. Medicina 1990;50:443.
77. Duchin JS, Koster F, Peters CJ, et al. Hantavirus pulmonary syndrome: A clinical description of 17 patients with a newly recognized disease. N Engl J Med 1994;330:949-955.
78. Khan AS, Khabbaz RF, Armstrong LR, et al. Hantavirus pulmonary syndrome - The first 100 US cases. J Infect Dis 1996;173:1297-303.
79. Colby TV, Zaki SR, Feddersen RM, Nolte KB. Hantavirus pulmonary syndrome is distinguishable from acute interstitial pneumonia. Arch Pathol Lab Med 2000;124:1463-6.
80. Moolenaar RL, Dalton C, Lipman HB, et al. Clinical features that differentiate hantavirus pulmonary syndrome from three other acute respiratory illnesses. Clin Infect Dis 1995;21:643-9.
81. Boroja M, Barrie JF, Raymond GS. Radiographic findings in 20 patients with Hantavirus pulmonary syndrome correlated with clinical outcome. Am J Roentgenol 2002;178:159-63.
82. Ketai LH, Williamson MR, Telepak RJ, et al. Hantavirus pulmonary syndrome-radiographic findings in 16 patients. Radiology 1994;191:665-8.
83. Vanderford V. Hantaviruses: An overview and radiographic correlation. Radiol Technol 1999;70:373-7.
84. Bustamante EA, Levy H, Simpson SQ. Pleural fluid characteristics in hantavirus pulmonary syndrome. Chest 1997;112:1133-6.
85. Hallin GW, Simpson SQ, Crowell RE, et al. Cardiopulmonary manifestations of hantavirus pulmonary symptoms. Crit Care Med 1996;24:252-8.
86. Centers for Disease Control and Prevention. Hantavirus pulmonary syndrome-Chile, 1997. MMWR 1997;46:949-951.
87. Hjelle B, Goade D, Torrez-Martinez N, et al. Hantavirus pulmonary syndrome, renal insufficiency, and myositis associated with infection by Bayou hantavirus. Clin Infect Dis 1996;23:495-500.
88. Khan AS, Gaviria M, Rollin PE, et al. Hantavirus pulmonary syndrome in Florida: Association with the newly identified Black Creek Canal virus. Am J Med 1996;100:46-8.
89. Khan AS, Spiropoulou CF, Morzunov S, et al. Fatal illness associated with a new hantavirus in Louisiana. J Med Virol 1995;46:281-6.
90. Levis S, Morzunov SP, Rowe JE, et al. Genetic diversity and epidemiology of hantaviruses in Argentina. J Infect Dis 1998;177:529-38.
91. Parisi MDN, Enria DA, Pini NC, Sabattini MS. Retrospective detection of clinical infections caused by hantavirus in Argentina. Medicina-Buenos Aires 1996;56:1-13.
92. Nolte KB, Feddersen RM, Foucar K, et al. Hantavirus pulmonary syndrome in the United States: A pathological description of a disease caused by a new agent. Hum Pathol 1995;26:110-20.
93. Khan AS, Ksiazek TG, Peters CJ. Hantavirus pulmonary syndrome. Lancet 1996;347:739-41.
94. Zaki S, Greer PW, Coffield LM, et al. Hantavirus pulmonary syndrome: Pathogenesis of an emerging infectious disease. Am J Pathol 1995;146:552-79.
95. Bruno P, Hassell LH, Brown J, Tanner W, Lau A. The protean manifestations of hemorrhagic fever with renal syndrome. A retrospective review of 26 cases from Korea. Ann Intern Med 1990;113:385-91.
96. Earle DP. Analysis of sequential physiologic derangements in epidemic hemorrhagic fever. With a commentary on management. Am J Med 1954;16:690-709.
97. Sheedy JA, Froeb HF, Batson HA, et al. The clinical course of epidemic hemorrhagic fever. Am J Med 1954;16:619-28.
98. Kim YS, Ahn C, Han JS, Kim S, Lee JS, Lee PW. Hemorrhagic fever with renal syndrome caused by the Seoul virus. Nephron 1995;71:419-27.
99. Park SC, Pyo HJ, Soe JB, et al. A clinical study of hemorrhagic fever with renal syndrome caused by Seoul virus infection. Korean J Intern Med 1989;4:130-5.
100. Lee M, Kim BK, Kim S, et al. Coagulopathy in hemorrhagic fever with renal syndrome (Korean hemorrhagic fever). Rev Infect Dis 1989;11:S877-83.
101. Kim YS, Lee JS, Ahn C, et al. Magnetic resonance imaging of the kidney in hemorrhagic fever with renal syndrome: Its histopathologic correlation. Nephron 1997;76:477-80.
102. Koh CS, Kim WD, Lee JS, Lee MH. Clinical study of Korean hemorrhagic fever. Korean Journal of Medicine 1972;15:757-66.
103. Lee JS, Han JS, Kim S, Chang KH. Panhypopituitarism in the acute stage of hemorrhagic fever with renal syndrome: A case report. Arch Virol 1990;1(Suppl):S95-100.
104. Valiakhmetov RZ, Gafarov AI, Memkhes VS, Galimzianov VZ. Spontaneous rupture of the kidneys in hemorrhagic fever with renal syndrome. Urologiia I Nefrologiia 1990;6:50-3.
105. Glass GE, Watson AJ, LeDuc JW, Kelen GD, Quinn TC, Childs JE. Infection with a ratborne hantavirus in US residents is consistently associated with hypertensive renal disease. J Infect Dis 1993;167:614-20.
106. LeDuc JW, Childs JE, Glass GE. The Hantaviruses, etiologic agents of hemorrhagic fever with renal syndrome: A possible cause of hypertension and chronic renal disease in the United States. Annu Rev Public Health 1992;13:79-98.
107. Rotz LD, Khan AS, Lillibridge SR, Ostroff SM, Hughes JM. Public health assessment of potential biological terrorism agents. Emerg Infect Dis 2002;8:225-30.
108. Crowley MR, Katz RW, Kessler R, et al. Successful treatment of adults with severe Hantavirus pulmonary syndrome with extracorporeal membrane oxygenation. Crit Care Med 1998;26:409-14.
109. Rosenberg RB, Waagner DC, Romano MJ, Kanase HN, Young RB. Hantavirus pulmonary syndrome treated with inhaled nitric oxide. Pediatr Infect Dis J 1998;17:749-52.
110. Bystrovskii VF. Effect of glucocorticoid hormones on the status of the hypothalamohypophyseal-adrenal system and endocrine function of the pancreas in patients with hemorrhagic fever with renal syndrome. Klinicheskaya Meditsina 1990;68:86-9.
111. Futrakul P, Poshyachinda M, Mitrakul C, et al. Hemodynamic response to high-dose methylprednisolone and mannitol in severe dengue-shock patients unresponsive to fluid replacement. Southeast Asian J Trop Med Public Health 1987;18:373-9.
112. Qian DY, Ding YS, Chen GF, et al. A placebo-controlled clinical trial of prednisone in the treatment of early hemorrhagic fever. J Infect Dis 1990;162:1213-4.
113. Sayer WJ, Entwisle GM, Uyeno BT, Bignall RC. Cortisone therapy of early epidemic hemorrhagic fever: A preliminary report. Ann Intern Med 1955;42:839-51.
114. Tassniyom S, Vasanawathana S, Chirawatkul A, Rojanasuphot S. Failure of high-dose methylprednisolone in established dengue shock syndrome: A placebo-controlled, doubleblind study. Pediatrics 1993;92:111-5.
115. Barry M, Russi M, Armstrong L, et al. Treatment of a laboratory-acquired Sabia virus infection. N Engl J Med 1995;333:294-6.
116. Enria D, Maiztegui JI. Antiviral treatment of Argentine hemorrhagic fever. Antiviral Res 1994;23:23-31.
117. Kilgore PE, Ksiazek TG, Rollin PE, et al. Treatment of Bolivian hemorrhagic fever with intravenous ribavirin. Clin Infect Dis 1997;24:718-22.
118. McKee KT Jr, Huggins JW, Trahan CJ, Mahlandt BG. Ribavirin prophylaxis and therapy for experimental argentine hemorrhagic fever. Antimicrob Agents Chemother 1988;32:1304-09.
119. Huggins JW, Hsiang C-M, Cosgriff TM, et al. Prospective, double-blind, concurrent, placebo-controlled clinical trial of intravenous ribavirin therapy of hemorrhagic fever with renal syndrome. J Infect Dis 1991;164:1119-27.
120. Chapman LE, Mertz GJ, Peters CJ, et al. Intravenous ribavirin for hantavirus pulmonary syndrome: Safety and tolerance during 1 year of open-label experience. Ribavirin study group. Antivir Ther 1999;4:211-9.
121. Enría DA, Briggiler AM, Fernández NJ, Levis SC, Maiztegui JI. Importance of dose of neutralising antibodies in treatment of Argentine haemorrhagic fever with immune plasma. Lancet 1984;ii:255-6.
122. Maiztegui JI, Fernández NJ, de Damilano AJ. Efficacity of immune plasma in treatment of Argentine haemorrhagic fever and association between treatment and a late neurological syndrome. Lancet 1979;ii:1216-7.
123. Enría DA, de Damilano AJ, Briggiler AM, et al. Sindrome neurologico tardio en enfermos de fiebre hemorrágica Argentina tratados con plasma immune. Medicina 1985;45:615-20.
124. Gubler DJ. Aedes aegypti and Aedes aegypti-borne disease control in the 1990s: Top down or bottom up. Am J Trop Med Hyg 1989;40:571-8.
125. Yap HH, Chong NL, Foo AE, Lee CV. Dengue vector control: Present status and future prospects. Gaoxiong Yi Xue Ke Xue Za Zhi 1994;10(Suppl):S102-8.
126. Gubler DJ, Clark GG. Community involvement in the control of Aedes aegypti. Acta Trop 1996;61:169-79.
127. Gratz NG, Jany WC. What role for insecticides in vector control programs? Am J Trop Med Hyg 1994;50:11-20.
128. Centers for Disease Control and Prevention. Fever, jaundice, and multiple organ system failure associated with 17D-derived yellow fever vaccination, 1996-2001. MMWR 2001;50:643-5.
129. Chan RC, Penney DJ, Little D, Carter IW, Roberts JA, Rawlinson WD. Hepatitis and death following vaccination with 17D-204 yellow fever vaccine. Lancet 2001;358:121-2.
130. Kelso JM, Mootrey GT, Tsai TF. Anaphylaxis from yellow fever. J Allergy Clin Immunol 1999;4:698-701.
131. Martin M, Tsai TF, Cropp B, et al. Fever and multisystem organ failure associated with 17D-204 yellow fever vaccination: A report of four cases. Lancet 2001;358:98-104.
132. Vasconcelos PF, Luna EJ, Galler R, et al. Serious adverse events associated with yellow fever 17D vaccine in Brazil: A report of two decades. Lancet 2001;358:91-7.
133. Osinusi K, Akinkugbe FM, Akinwolere OA, Fabiyi A. Safety and efficacy of yellow fever vaccine in children less than one-year-old. West Afr J Med 1990;9:200-203.
134. Robert E, Vial T, Schaefer C, Arnon J, Reuvers M. Exposure to yellow fever vaccine in early pregnancy. Vaccine 1999;17:283-5.
135. Leder K, Weller PF, Wilson ME. Travel vaccines and elderly persons: Review of vaccines available in the United States. Clin Infect Dis 2001;33:1553-66.
136. Martin M, Weld L, Tsai TF, et al. Advances age risk factor for illness temporally associated with yellow fever vaccination. Emerg Infect Dis 2001;7:945-51.
137. Receveur MC, Thiebaut R, Vedy S, Malvy D, Mercie P, Bras ML. Yellow fever vaccination of human immunodeficiency virus-infected patients: Report of 2 cases. Clin Infect Dis 2000;31:E7-8.
138. Sibailly TS, Wiktor SZ, Tsai TF, et al. Poor antibody response to yellow fever vaccination in children infected with human immunodeficiency virus type 1. Pediatr Infect Dis J 1997;16:1177-9.
139. Barrett AD. Current status of flavivirus vaccines. Ann NY Acad Sci 2001;951:262-71.
140. Kilgore PE, Peters CJ, Mills JN, et al. Prospects for the control of Bolivian hemorrhagic fever. Emerg Infect Dis 1995;1:97-100.
141. Mercado RR. Rodent control programmes in areas affected by Bolivian haemorrhagic fever. Bull World Health Organ 1975;52:691-6.
142. Maiztegui JI, McKee Jr KT, Barrera Oro JG. et al. Protective efficacy of a live attenuated vaccine against Argentine hemorrhagic fever. J Infect Dis 1998;177:277-83.
143. Centers for Disease Control and Prevention. Hantavirus infection-Southwestern United States. Interim recommendations for environmental clean-up and risk reduction. MMWR 1993;42:1-13.
144. Glass GE, Johnson JS, Hodenbach GA, et al. Experimental evaluation of rodent exclusion methods to reduce hantavirus transmission to humans in rural housing. Am J Trop Med Hyg 1997;56:359-64.
145. Centers for Disease Control. Update: Management of patients with suspected viral hemorrhagic fever - United States. MMWR 1995;44:475-9.
146. Centers for Disease Control and Prevention. Management of patients with suspected viral hemorrhagic fever. MMWR 1988;37:1-16.
147. Peters CJ, Jahrling PB, Khan AS. Patients infected with high-hazard viruses: Scientific basis for infection control. Arch Virol 1996;11:141-68.